FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| STATEMENT | OF C | HANGES | IN BENE | FICIAL | OWNERSHIP |
|-----------|------|--------|---------|--------|-----------|

| OMB APPROVAL | | | | | | | | | |
|----------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | |
| Estimated average be | urden | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

| | | | | | Or | Sect | ion 30(n) (| or the | INVE | esunent | Com | npany Act | 01 1940 | | | | | | | | |
|---|--|--|---|---|---|-------|--|--------|--|--|----------|---|---------------------------------|--|---|---|---|-----------------------------------|--|---|--|
| Name and Address of Reporting Person* <u>Vitorovic Stefan</u> | | | | 2. Issuer Name and Ticker or Trading Symbol Vigil Neuroscience, Inc. [VIGL] | | | | | | | | | (Che | elationship eck all appli Direct | cable) | ig Pers | son(s) to Iss 10% Ov | | | | |
| | EUROSCI | ENCE, INC. | (Middle) | | 3. Date of Earliest Transaction (Month/Day/Year) 06/09/2022 | | | | | | | | | | Office below | (give title | | Other (s below) | specify | | |
| 1 BROADWAY, 7TH FLOOR, SUITE 07-300 | | | | 4.1 | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | | |
| (Street) | IDGE M | IA | 02142 | | | | | | | | | | | | - 1 | Form | iled by Mo | | orting Perso n One Repo | I | |
| (City) | (5 | State) | (Zip) | | | | | | | | | | | | | | | | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Trans: Date (Month/L | | | | action 2A. Deemed Execution Date, if any (Month/Day/Year | | | , Transaction Disposed Code (Instr. 5) | | | ities Acquired (A) or d Of (D) (Instr. 3, 4 a | | | Beneficially Owned Following | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership | | | | |
| | | | | | | | | | Code | v | Amount | (A | () or () | Price | Transac | Reported Transaction(s) (Instr. 3 and 4) | | | (Instr. 4) | | |
| Common Stock | | | | | | | | | | | | | | | 5,00 | 5,004,393 | | I | By Vida Ventures III, L.P. | | |
| Common Stock | | | | | | | | | | | | | | 11 | 11,536 | | I | By Vida Ventures III-A, .P. | | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | | |
| Derivative Conversion Date | | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution I if any (Month/Day | d 4 Date, | 4. Transa Code (I | ction | 5. Number of | | 6. Date Exercisa Expiration Date (Month/Day/Year | | able and | 7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4) | | mount | 8. Price of Derivative Security (Instr. 5) | 9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4) | Ownersh Form: Direct (D or Indire (I) (Instr. | Ownership | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | Code | v | (A) | (D) | Dat Exe | te ercisabl | | xpiration ate | Title | OI N | umber | | | | | | |
| Stock Option Grant (Right to Buy) | \$3.1 | 06/09/2022 | | | A | | 12,155 | | | (3) | 00 | 6/09/2032 | Comm | | 2,155 | \$0.00 | 12,15 | 5 | D | | |

Explanation of Responses:

- 1. The shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of of Vida III. The Reporting Person is a managing member of Vida III GP and disclaims beneficial ownership of the shares held directly by Vida III, except to the extent of his pecuniary interest therein, if any.
- 2. The shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of of Vida III-A. The Reporting Person is a managing member of Vida III GP and disclaims beneficial ownership of the shares held directly by Vida III-A, except to the extent of his pecuniary interest therein, if any.
- 3. The shares subject to this option shall vest and become exercisable upon the earlier to occur of (i) June 9, 2023 and (ii) the next annual meeting of the Issuer's stockholders.

Remarks:

/s/ Jennifer Ziolkowski, Attorney-in-Fact

06/13/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.